Biolight Life Sciences

Business Overview

DESCRIPTION

We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome, or DES, and age-related macular degeneration, or AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications.

Leading key investors, holding about 60% of BioLight’s issued and outstanding shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel and Rock One A Hong Kong investment based company.

BioLight is a public traded company on the Tel-Aviv Stock Exchange (BOLT).

FOUNDED
2009
INVESTOR TYPE
Company
MODEL PREFERENCE
B2B
SERIES PREFERENCE
Series B
OFFERING PREFERENCE
Hardware, Software
AI TYPE PREFERENCE
Computer Vision
SECTORS
Healthcare Non-invasive Ophthalmology

Team

Biolight Life Sciences
Yaacov Michlin
CEO

Active Investment Portfolio

Startup

Operating Status

Offering Type

Business Model

Total Funding

AI Employees

Belkin Laser
Active
Hardware, Software
B2B
$25.3 M
2

Exited Investment Portfolio

Startup

Operating Status

Offering Type

Business Model

Total Funding

AI Employees

Investment Rounds History

Startup

Date Announced

Amount Raised

Funding Round

July 2020
$12.25 million
Series B